These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30991119)

  • 1. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
    Ding F; Liu B; Wang Y
    J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis.
    Li J; Gu J
    Crit Rev Oncol Hematol; 2017 Nov; 119():50-58. PubMed ID: 29065985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
    Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
    Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.
    Fischer A; Wu S; Ho AL; Lacouture ME
    Invest New Drugs; 2013 Jun; 31(3):787-97. PubMed ID: 23345001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
    Wang S; Yang Z; Wang Z
    Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.
    Qi WX; Shen Z; Tang LN; Yao Y
    Br J Clin Pharmacol; 2014 Oct; 78(4):748-62. PubMed ID: 24661224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
    Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
    Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials.
    Qi WX; Tang LN; Sun YJ; He AN; Lin F; Shen Z; Yao Y
    Ann Oncol; 2013 Dec; 24(12):2943-52. PubMed ID: 23921791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
    Massey PR; Okman JS; Wilkerson J; Cowen EW
    Support Care Cancer; 2015 Jun; 23(6):1827-35. PubMed ID: 25471178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
    Belum VR; Wu S; Lacouture ME
    Invest New Drugs; 2013 Aug; 31(4):1078-86. PubMed ID: 23700287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Schutz FA; Je Y; Richards CJ; Choueiri TK
    J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis.
    Zhang ZF; Wang T; Liu LH; Guo HQ
    PLoS One; 2014; 9(3):e90135. PubMed ID: 24621598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association between hand-foot skin reaction and effectiveness of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma].
    Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Yihebali C; Zhou AP; Wang JW; Sun Y
    Zhonghua Yi Xue Za Zhi; 2016 Sep; 96(34):2717-2721. PubMed ID: 27667104
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis.
    Qi WX; Shen Z; Tang LN; Yao Y
    Crit Rev Oncol Hematol; 2014 Nov; 92(2):71-82. PubMed ID: 24878433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition.
    Hasan Alshammari A; Masuo Y; Fujita KI; Shimada K; Iida N; Wakayama T; Kato Y
    Biochem Pharmacol; 2022 Mar; 197():114914. PubMed ID: 35041812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials.
    Zhang W; Feng LJ; Teng F; Li YH; Zhang X; Ran YG
    Expert Rev Clin Pharmacol; 2020 Mar; 13(3):311-320. PubMed ID: 32105149
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.
    Belum VR; Serna-Tamayo C; Wu S; Lacouture ME
    Clin Exp Dermatol; 2016 Jan; 41(1):8-15. PubMed ID: 26009777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Morgan CJ; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
    Crit Rev Oncol Hematol; 2015 May; 94(2):228-37. PubMed ID: 25577572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
    Balagula Y; Wu S; Su X; Feldman DR; Lacouture ME
    Invest New Drugs; 2012 Aug; 30(4):1773-81. PubMed ID: 21394443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.